Credit Suisse’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Credit Suisse’s Portfolio SIOX Stock Details SIOX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-58,085	Closed	-$362K	–	4307
2019 Q2	$362K	Buy	+58,085	New	+$442K	﹤0.01%	3587
2018 Q2	–	Sell	-4,658	Closed	-$50K	–	4196
2018 Q1	$50K	Buy	4,658 +118	+3%	+$1.9K	﹤0.01%	3880
2017 Q4	$191K	Sell	4,540 -472	-9%	-$21.2K	﹤0.01%	3756
2017 Q3	$276K	Buy	5,012 +2,858	+133%	+$482K	﹤0.01%	3784
2017 Q2	$399K	Buy	2,154 +187	+10%	+$32.8K	﹤0.01%	3302
2017 Q1	$235K	Sell	1,967 -2,550	-56%	-$267K	﹤0.01%	3589
2016 Q4	$450K	Buy	4,517 +484	+12%	+$51K	﹤0.01%	3500
2016 Q3	$451K	Buy	4,033 +2,299	+133%	+$276K	﹤0.01%	3471
2016 Q2	$178K	Buy	+1,734	New	+$173K	﹤0.01%	3907
2015 Q4	–	Sell	-4,615	Closed	-$477K	–	4402
2015 Q3	$477K	Buy	+4,615	New	+$541K	﹤0.01%	3429

Other funds holding SIOX

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

MWNA

Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Credit Suisse's SIOX Position: Q3 2019 in Review

Credit Suisse sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q3 2019, closing a stake of 58,085 shares — an estimated $362K sold.

Credit Suisse first reported a position in SIOX in Q3 2015 and held it in 10 quarters. The position peaked at $477K in Q3 2015. 48 funds tracked by Wall St. Rank hold SIOX as of Q3 2019.

Credit Suisse reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
Credit Suisse sold 58,085 Sio Gene Therapies Inc. Common Stock shares in Q3 2019, an estimated $362K.
Credit Suisse first reported a position in Sio Gene Therapies Inc. Common Stock in Q3 2015 and held it in 10 quarters.
Credit Suisse's Sio Gene Therapies Inc. Common Stock position peaked at $477K in Q3 2015.
48 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q3 2019.

Based on Credit Suisse's 13F filing for Q3 2019, filed 12 Nov 2019.